Targeting Triple-Negative Breast Cancer


Breast cancer may develop in one part of the body, but it’s not just one disease. In fact, oncologists think of breast cancer as at least three different types of diseases.

Erica Mayer, MD, MPH

Triple-negative breast cancer (TNBC) describes breast cancer cells that do not have estrogen, progesterone, or HER2 receptors. It makes up approximately 15 percent of all breast cancers and is typically more aggressive than the other two types, estrogen receptor-positive breast cancer and HER2-positive breast cancer.

“It may be the smallest group, but TNBC still represents thousands of women with breast cancer, so it is a very important group for us,” says Erica Mayer, MD, MPH, a medical oncologist at Dana-Farber’s Susan F. Smith Center for Women’s Cancers.

The Susan F. Smith Center for Women’s Cancers organized a live webcast with Mayer earlier this year titled, “Targeting Advanced Triple Negative Breast Cancer.” Mayer spoke about the improved chemotherapy options and clinical trials available for TNBC patients.

“TNBC is a very active area of research,” Mayer says. “We have many new, exciting agents in the pipeline.”

To view Mayer’s presentation, visit Dana-Farber’s Slideshare page.

Comments Sort By Newest

Leave a Reply

Your email address will not be published. Required fields are marked *

Blue Captcha Image


Latest Tweets

Dana-Farber @danafarber
"Expressive art therapy allows me to gain back a part of me that went away for awhile.”
Dana-Farber @danafarber
The Latest in Lung Cancer Treatment and Research: #lcsm
Dana-Farber @danafarber
Join us Dec. 15 to discuss the latest in prostate cancer research: #dfciwebchat

Make An Appointment

For adults: 877-442-3324

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.